Recent Posts
Connect with:
Wednesday / April 17.
HomemiproductsResearching Targeted C3 Therapies

Researching Targeted C3 Therapies

A leader in the research of targeted C3 therapies, Apellis was established in 2009 with the ambition to develop life-changing medicines for people with complement-driven diseases, including those within haematology, ophthalmology, neurology, and nephrology.

Targeting complement proteins centrally at the level of C3 is a novel therapeutic approach that may have potential for treatment of geographic atrophy in age-related macular degeneration.

Visit: apellis.com